[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604638":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":31,"studyPopulation":32,"armGroups":33,"interventions":39,"overallOfficials":47,"centralContacts":51,"locations":56,"responsibleParty":67,"collaborators":11,"id":69,"slug":11,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":11,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":11,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":11,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Pfizer","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":11},[9,13,15,17],{"measure":10,"description":11,"timeFrame":12},"Frequency and proportion of AEs\u002FADRs",null,"24 weeks (Regular surveillance), 48 weeks (Long-term surveillance)",{"measure":14,"description":11,"timeFrame":12},"Frequency and proportion of unexpected AEs\u002FADRs",{"measure":16,"description":11,"timeFrame":12},"Frequency and proportion of SAEs\u002FSADRs",{"measure":18,"description":11,"timeFrame":12},"Frequency and proportion of AESI",[20,22,24,26],{"measure":21,"description":11,"timeFrame":12},"Proportion of patients achieving Severity of Alopecia Tool (SALT) ≤20 score at Weeks 24 and 48",{"measure":23,"description":11,"timeFrame":12},"Proportion of patients achieving SALT ≤10 score at Weeks 24 and 48",{"measure":25,"description":11,"timeFrame":12},"Proportion of patients achieving 50% or above improvement in SALT score from baseline (SALT 50) at Weeks 24 and 48",{"measure":27,"description":11,"timeFrame":12},"Proportion of patients achieving 75% or above improvement in SALT score from baseline (SALT 75) at Weeks 24 and 48",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":29,"timePerspective":30,"maskingInfo":11},"COHORT","PROSPECTIVE","To evaluate the safety of Litfulo Capsule after marketing, with regard to the following clauses in routine clinical practice.\n\n* Adverse Events (AEs)\u002F Adverse Drug Reactions (ADRs)\n* Unexpected Adverse Events (AEs)\u002FADRs that have not been reflected in the approved drug label\n* Serious Adverse Events (SAEs)\u002FSerious Adverse Drug Reaction (SADRs)\n* Adverse Event of Special Interest(AESI)\n\n  * Serious Infections, defined as any infection (viral, bacterial, and fungal) requiring parenteral antimicrobial therapy or hospitalization for treatment or meeting other criteria that require the infection to be classified as serious adverse event\n  * Opportunistic infections and Herpes Zoster\n  * Malignancy","Patients with severe alopecia areata",[34],{"label":35,"type":11,"description":36,"interventionNames":37},"Patients with severe alopecia areata.","Determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product.",[38],"Drug: Litfulo",[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"DRUG","Litfulo","as provided in real world practice.",[35],[46],"Ritlecitinib tosylate (ATC code: L04AF08)",[48],{"name":49,"affiliation":5,"role":50},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[52],{"name":49,"role":53,"phone":54,"phoneExt":11,"email":55},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[57],{"facility":5,"status":58,"city":59,"state":11,"zip":11,"country":60,"countryCode":11,"cosmosGeoPoint":61,"geoPoint":66,"contacts":11},"RECRUITING","Seoul","South Korea",{"type":62,"coordinates":63},"Point",[64,65],126.9784,37.566,{"lat":65,"lon":64},{"type":68,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100604638",false,"NCT07152119","A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.","KOREAN POST MARKETING SURVEILLANCE FOR LITFULO CAPSULE","Inclusion Criteria:\n\nPatients with severe alopecia areata who have been determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product Treatment of severe alopecia areata in adults and adolescents 12 years or older Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)\u002Flegal guardian, if applicable, have been informed of all pertinent aspects of the study","ALL","12 Years",{"count":78,"type":79},3000,"ESTIMATED","OBSERVATIONAL","The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.",[83],"Severe Alopecia Areata",[42,85,86],"Litfulo capsule","Ritlecitinib tosylate","2026-05-14",{"date":89,"type":90},"2026-05-18","ACTUAL",{"date":92,"type":90},"2025-08-27",{"date":94,"type":79},"2030-03-23",{"name":5,"class":6},1]